PL3659614T3 - Onkolityczny wirus krowianki - Google Patents

Onkolityczny wirus krowianki

Info

Publication number
PL3659614T3
PL3659614T3 PL19203305.8T PL19203305T PL3659614T3 PL 3659614 T3 PL3659614 T3 PL 3659614T3 PL 19203305 T PL19203305 T PL 19203305T PL 3659614 T3 PL3659614 T3 PL 3659614T3
Authority
PL
Poland
Prior art keywords
vaccinia virus
oncolytic vaccinia
oncolytic
virus
vaccinia
Prior art date
Application number
PL19203305.8T
Other languages
English (en)
Inventor
Yaohe Wang
Robert Nicholas Lemoine
Ming Yuan
Jahangir AHMED
Original Assignee
Queen Mary University Of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary University Of London filed Critical Queen Mary University Of London
Publication of PL3659614T3 publication Critical patent/PL3659614T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C12N2710/24162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL19203305.8T 2014-04-01 2015-04-01 Onkolityczny wirus krowianki PL3659614T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1405834.1A GB201405834D0 (en) 2014-04-01 2014-04-01 Oncolytic virus

Publications (1)

Publication Number Publication Date
PL3659614T3 true PL3659614T3 (pl) 2023-10-09

Family

ID=50737799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19203305.8T PL3659614T3 (pl) 2014-04-01 2015-04-01 Onkolityczny wirus krowianki

Country Status (13)

Country Link
US (2) US20170020938A1 (pl)
EP (2) EP3659614B9 (pl)
JP (1) JP6616319B2 (pl)
KR (1) KR102409147B1 (pl)
CN (1) CN106795527B (pl)
ES (1) ES2954676T3 (pl)
GB (1) GB201405834D0 (pl)
HR (1) HRP20231025T1 (pl)
HU (1) HUE062816T2 (pl)
PL (1) PL3659614T3 (pl)
RS (1) RS64497B1 (pl)
SM (1) SMT202300224T1 (pl)
WO (1) WO2015150809A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510143A (ja) 2015-02-25 2018-04-12 メモリアル スローン ケタリング キャンサー センター 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
HRP20231299T1 (hr) 2016-01-11 2024-02-02 Queen Mary University Of London Inhibitori pi3k p-delta 110 za uporabu u isporuci virusa u liječenju raka
SG11201807022XA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN116440176A (zh) 2016-02-25 2023-07-18 纪念斯隆凯特琳癌症中心 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
WO2017209053A1 (ja) * 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US20200046784A1 (en) * 2016-09-30 2020-02-13 University Health Network Recombinant oncolytic viruses for cancer therapy
CN110381997A (zh) * 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
CA3088609C (en) * 2018-01-19 2024-02-13 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
CN110101843A (zh) * 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2020056424A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
MY206167A (en) 2018-09-26 2024-12-03 Astellas Pharma Inc Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
GB201816547D0 (en) * 2018-10-10 2018-11-28 Univ London Queen Mary Oncolytic virus for the treatment of cancer
CN114144196B (zh) * 2019-07-12 2024-03-08 深圳市华药康明生物药业有限责任公司 工程痘苗病毒
JP2022547234A (ja) 2019-08-29 2022-11-10 アステラス製薬株式会社 遺伝子操作された腫瘍溶解性ワクシニアウイルスおよびその使用方法
EP4031165A4 (en) * 2019-09-20 2023-10-11 University of Pittsburgh - Of the Commonwealth System of Higher Education ONCOLYTIC VIRUSES EXPRESSING IL-36 CYTOKINE FOR THE TREATMENT OF CANCER
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP7659395B2 (ja) 2020-02-06 2025-04-09 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
CN115103681B (zh) * 2020-02-18 2023-10-31 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途
WO2022109503A1 (en) * 2020-11-23 2022-05-27 Devacell, Inc. Recombinant oncolytic viruses, surface-engineered delivery systems and related methods
WO2022115767A1 (en) * 2020-11-30 2022-06-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of treating cancer
CN115820739B (zh) * 2022-11-23 2025-04-04 郑州大学 一种单拷贝vgf基因溶瘤痘苗病毒载体的构建方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955310A (en) * 1998-02-26 1999-09-21 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide in a bacillus cell
WO2003082212A2 (en) * 2002-03-27 2003-10-09 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for treating cancer in humans
CA2558771C (en) * 2004-03-05 2013-01-08 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of rnai agents
CN1560248A (zh) * 2004-03-10 2005-01-05 中国疾病预防控制中心性病艾滋病预防 IFN-γ受体基因(B8R)缺失的天坛株重组痘苗病毒及用途
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
CA2629163C (en) * 2005-11-10 2017-03-21 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2008100292A2 (en) * 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
CN101658670A (zh) * 2008-08-25 2010-03-03 中国疾病预防控制中心性病艾滋病预防控制中心 基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗
EP2199400A1 (en) * 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
CA2795695A1 (en) * 2010-04-09 2011-10-13 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
CN102206679B (zh) * 2011-03-30 2013-03-13 中国人民解放军军事医学科学院军事兽医研究所 一种痘苗病毒穿梭载体及其应用
CN103110939A (zh) * 2012-10-23 2013-05-22 郑州大学 诱导肿瘤特异性免疫的疫苗及其应用
CN103305477B (zh) * 2013-06-08 2014-12-03 中国人民解放军疾病预防控制所 痘苗病毒的gfp示踪系统及其应用

Also Published As

Publication number Publication date
EP3659614A1 (en) 2020-06-03
EP3126505A1 (en) 2017-02-08
KR20170003920A (ko) 2017-01-10
ES2954676T3 (es) 2023-11-23
HRP20231025T1 (hr) 2023-12-08
JP2017511136A (ja) 2017-04-20
RS64497B1 (sr) 2023-09-29
EP3659614C0 (en) 2023-06-07
US20230293608A1 (en) 2023-09-21
GB201405834D0 (en) 2014-05-14
CN106795527A (zh) 2017-05-31
EP3659614B1 (en) 2023-06-07
SMT202300224T1 (it) 2023-09-06
EP3126505B1 (en) 2019-10-16
KR102409147B1 (ko) 2022-06-16
WO2015150809A1 (en) 2015-10-08
EP3659614B9 (en) 2023-10-04
CN106795527B (zh) 2020-10-30
US20170020938A1 (en) 2017-01-26
HUE062816T2 (hu) 2023-12-28
JP6616319B2 (ja) 2019-12-04

Similar Documents

Publication Publication Date Title
IL279154B (en) Adenovirus-related vector
PL3659614T3 (pl) Onkolityczny wirus krowianki
IL260480B (en) Oncolytic virus modifications
GB201406608D0 (en) Virus
EP3795697C0 (en) GENOME FRACTIONATION
GB201410971D0 (en) Vaccine
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
GB201609143D0 (en) Winglet
GB201609142D0 (en) Winglet
LT3237349T (lt) Patobulintas biologinis rišiklis
GB201419572D0 (en) Virus
IL247535A0 (en) Fox-viral oncolytic vectors
SG10201404371VA (en) Improved dry block assembly
GB201610959D0 (en) Winglet
PT3188755T (pt) Vacina
GB2522661B (en) Context configuration
GB201417214D0 (en) Vaccine
GB201406628D0 (en) Vaccine
GB201522317D0 (en) Chimeric oncolytic virus
GB201406470D0 (en) Virus
GB201403582D0 (en) Virus
GB201522013D0 (en) Virus
GB201621665D0 (en) Chimeric oncolytic virus
GB201516936D0 (en) Virus
GB201507419D0 (en) Virus